Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Another Fidelis dismissal

This article was originally published in The Gray Sheet

Executive Summary

Minnesota state judge dismisses more than 600 personal injury suits, including 14 distinct liability claims, against Medtronic related to its discontinued 7-French Sprint Fidelis defibrillator lead. The Oct. 20 dismissal 1order cites federal pre-emption protection for the FDA-approved product and follows a similar ruling in January in federal multi-district litigation (2"The Gray Sheet" Jan. 12, 2009). In both cases, the judges rejected plaintiffs' arguments that their claims were "parallel" to rather than in addition to FDA requirements and that the Class I recall of Fidelis invalidated its PMA supplement approval. Legislation to reverse the 2008 U.S. Supreme Court decision that forms the basis of these rulings is still pending in Congress (3"The Gray Sheet" Aug. 10, 2009)

You may also be interested in...

Senate Dems Argue That Device Safety Act Will Not Curb Innovation

Senate Democrats are challenging the notion that removing federal pre-emption protection for PMA-approved devices, solidified last year by the Supreme Court, will stifle innovation

Judge Wields Pre-emption To Dismiss Medtronic Fidelis Claims

A Minnesota federal judge on Jan. 5 categorically 1dismissed on grounds of federal pre-emption all 21 claims in a multidistrict personal injury lawsuit against Medtronic for its Sprint Fidelis implantable defibrillator leads

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts